The European Exchange- India–Europe Life Sciences, Deep Tech & Cross-Border Capital Roundtable
The European Exchange - A closed-door capital conversation on India–Europe life sciences corridors, cross-border capital flows, and the institutional pathways connecting two of the world's most active healthcare ecosystems.
European institutional capital is looking at India. The appetite is real- European LPs in life sciences, deep tech, and climate health are sitting on significant dry powder with limited domestic deployment opportunities that meet their return requirements. India's life sciences sector- pharma, bioscience, CDMO, health-tech- is generating exactly the deal flow they are looking for.
The problem is not the capital. The problem is not the companies. The problem is the organized institutional pathway between them does not yet exist at scale.
A European life sciences LP in Amsterdam or a biotech licensing fund in London has no structured way to access curated Indian deal flow that matches their mandate, meets their governance standards, and comes through a relationship they trust. An Indian pharma or bioscience company with a genuine European expansion thesis has no organized route into the LP networks, NHS innovation partnerships, or EMA regulatory pathways that would make that expansion credible.
The European Exchange is a closed-door virtual room for twelve to fifteen investors, founders, IBs, and institutional professionals actively operating across the India–Europe life sciences corridor. Not a panel. Not a networking event. A structured 90-minute conversation among people on both ends of the corridor who are motivated to make it work- and who need the right room to find each other.
What the room will cover
→ What are European institutional investors actually looking for in Indian life sciences in 2026 — which sub-sectors, what stages, what governance and regulatory standards are the minimum thresholds for a European LP to engage?
→ What does a well-structured India–Europe life sciences partnership look like in practice- licensing, co-development, equity, or distribution-and what are the regulatory, cultural, and operational barriers that kill corridor deals before they close?
→ NHS collaboration, MHRA regulatory pathways, and the UK biotech licensing ecosystem- where are the concrete entry points for Indian life sciences companies, and what does corridor readiness actually require?
→ From the India side- which Indian pharma, bioscience, and health-tech companies are genuinely Europe-ready in 2026, and what separates them from companies that have a European ambition but not yet a European strategy?
What you leave with
Every participant receives a post-room intelligence brief within 72 hours -European mandate map, corridor deal structure intelligence, EMA and MHRA regulatory pathway summary, and deal flow signals from both ends of the corridor. Exclusive to the room.
Who is in the room
European LP and pan-European life sciences fund representatives · India-based family office principals with European co-investment networks · Indian life sciences and pharma company founders with active European mandates · UKIBC, Indo-German Chamber, and bilateral trade body representatives · Genesis London presence professionals · European regulatory affairs advisors · Healthcare IBs with India–Europe corridor experience
Participation is by invitation only. The room is composed — not open. Participants from the Q2 series — Well Capitalised, Pulse Check, and Licensed to Scale — are invited to continue the conversation here.
HOSTED BY
TCR Healthcare- a private capital coordination platform operating across India's healthcare and life sciences sector. Licensed to Scale is the third room in TCR's 2026 Healthcare Roundtable Series, convened in partnership with Genesis.
EVENT DETAILS BLOCK
📅 First Thursday · May 2026
🕐 90 Minutes
💻 Virtual · Google Meet
🔒 By Invitation Only · 12–15 Participants
📄 Post-Room Intelligence Report included
This is a private, invitation-only event hosted by The Capital Room (TCR). Registrations are reviewed before confirmation. All room discussions are confidential and not for public attribution.